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Objectives To determine whether venous congestion, rather than impairment of cardiac output, is primarily associated with the
development of worsening renal function (WRF) in patients with advanced decompensated heart failure (ADHF).
Background Reduced cardiac output is traditionally believed to be the main determinant of WRF in patients with ADHF.
Methods A total of 145 consecutive patients admitted with ADHF treated with intensive medical therapy guided by pulmo-
nary artery catheter were studied. We defined WRF as an increase of serum creatinine 0.3 mg/dl during
hospitalization.
Results In the study cohort (age 57  14 years, cardiac index 1.9  0.6 l/min/m2, left ventricular ejection fraction 20 
8%, serum creatinine 1.7  0.9 mg/dl), 58 patients (40%) developed WRF. Patients who developed WRF had a
greater central venous pressure (CVP) on admission (18  7 mm Hg vs. 12  6 mm Hg, p  0.001) and after
intensive medical therapy (11  8 mm Hg vs. 8  5 mm Hg, p  0.04). The development of WRF occurred less
frequently in patients who achieved a CVP 8 mm Hg (p  0.01). Furthermore, the ability of CVP to stratify risk
for development of WRF was apparent across the spectrum of systemic blood pressure, pulmonary capillary
wedge pressure, cardiac index, and estimated glomerular filtration rates.
Conclusions Venous congestion is the most important hemodynamic factor driving WRF in decompensated patients with ad-
vanced heart failure. (J Am Coll Cardiol 2009;53:589–96) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.068o
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ihe pathophysiology of the cardiorenal interaction in the
etting of advanced decompensated heart failure (ADHF) is
oorly understood. It is commonly observed that coexisting
enal dysfunction may complicate the treatment course of
See page 597
eart failure (HF) and that the use of intravenous loop
iuretics often alleviate congestion at the cost of worsening
enal function (WRF) (1,2). Worsening renal function
uring treatment of patients with ADHF typically occurs
ithin days of hospitalization and is a strong independent
redictor of adverse outcomes (3–5).
rom the Department of Cardiovascular Medicine, Kaufman Center for Heart
ailure, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Dr. Tang
s supported in part by the National Institutes of Health, National Center for
esearch Resources, CTSA 1UL1RR024989, Cleveland, Ohio.A
Manuscript received February 8, 2008; revised manuscript received May 14, 2008,
ccepted May 19, 2008.Traditionally, WRF has been attributed to hypoperfusion
f the kidney due to progressive impairment of cardiac
utput or intravascular volume depletion secondary to over-
ealous use of diuretics (6). Although the majority of
atients hospitalized with ADHF also present with in-
reased central or peripheral congestion, the presence of
enous congestion has been considered a secondary phe-
omenon because of the “backward failure” caused by
mpaired cardiac output. Nevertheless, experimental animal
ata as far back as the 1930s have demonstrated that
emporary isolated elevation of central venous pressure
CVP) can be transmitted back to the renal veins, resulting
n direct impairment of renal function (7,8). However,
uman data regarding the differential contributions of
enous congestion and cardiac output in the development of
RF during ADHF are lacking.
The primary aim of this study is to test the hypothesis
hat WRF is more dependent on venous congestion than on
mpairment of cardiac output in patients admitted with
DHF. The secondary aim is to investigate if effective
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medical therapy can prevent the
development of WRF.
Methods
Subject population. We enrolled
consecutive subjects, age 18
years, with ADHF including New
York Heart Association functional
class III to IV symptoms who un-
derwent intensive medical therapy
guided by pulmonary artery cath-
eter (PAC) at the Cleveland Clinic
in a dedicated heart failure inten-
sive care unit between January 1,
2006, and June 30, 2007. Subjects
who met the following inclusion
riteria at the time of admission were enrolled in the study:
) left ventricular ejection fraction 30%; 2) cardiac index
CI) 2.4 l/min/m2; and 3) pulmonary capillary wedge
ressure (PCWP) 18 mm Hg and/or CVP 8 mm Hg.
xclusion criteria included: 1) mechanical ventilation; 2)
enal replacement therapy; 3) intravenous inotropic support
n admission; 4) congenital heart disease; and 5) recipients
f heart transplantation. Institutional review board approval
f this research project was obtained, and informed consent
as obtained for hospitalization and treatment and was
ocumented in the medical records, according to protocol
nd Cleveland Clinic policy.
ntensive medical therapy. The hemodynamic goals and
harmacologic approach of intravenous therapy in the
edicated heart failure intensive care unit have been previ-
usly described (9). In brief, optimal hemodynamic response
as defined as a decrease in PCWP to 18 mm Hg, a
ecrease in CVP to 8 mm Hg, and improvement in CI to
2.4 l/min/m2, all while maintaining mean arterial pressure
65 to 70 mm Hg. To achieve these hemodynamic goals,
ll subjects were treated according to protocols developed
n our intensive care unit with intravenous or oral loop
iuretics in combination with intravenous vasodilators
and/or inotropic agents), while continuing and optimizing
vidence-based therapies (angiotensin-converting enzyme
nhibitors, beta-blockers, and spironolactone) as tolerated.
ata collection and renal assessment. Two experienced
eart failure cardiologists manually collected hemodynamic
ata, demographic characteristics, treatment, and echocar-
iographical data. Sequential serum creatinine and blood
rea nitrogen values were recorded on admission and daily
hroughout the hospitalization period, including the day of
ischarge. We defined a strict definition on the develop-
ent of WRF as an increase in serum creatinine of 0.3
g/dl during hospitalization, consistent with several previ-
us investigations (4,5,10). It takes into account any signif-
cant renal deterioration during the treatment period in the
Abbreviations
and Acronyms
ADHF  advanced
decompensated heart
failure
CI  cardiac index
CVP  central venous
pressure
GFR  glomerular filtration
rate
PAC  pulmonary artery
catheter
PCWP  pulmonary
capillary wedge pressure
WRF  worsening renal
functionetting of low cardiac output and congestion as defined by mhe inclusion criteria. Glomerular filtration rate (GFR) in
illiliters per minute was estimated daily by the use of the
-variable Modification of Diet in Renal Disease equation
11). Normal or mild renal insufficiency was defined as GFR
60 ml/min/1.73 m2. Moderate renal insufficiency was
efined as GFR 30 to 59 ml/min/1.73 m2 and severe renal
nsufficiency as GFR 30 ml/min/1.73 m2.
emodynamic assessment. Complete hemodynamic as-
essment was collected in all subjects before the start of
ntensive medical therapy and again before removing the
AC. The CVP and PCWP were assessed at end-
xpiration with a balloon-tipped catheter at steady state
ith the subject in a supine position. The CI was calculated
y use of the Fick equation through sampling of a mixed
entral venous blood gas taken in the pulmonary artery
hile assuming standard metabolic rates. The systemic
lood pressure was measured noninvasively by an automatic
uff sphygmomanometer. Renal perfusion pressure on ad-
ission was assessed as the difference between mean arterial
ressure and central venous pressure.
tatistical analysis. All data were expressed as mean SD
or continuous data (median [interquartile range] for non-
arametric data) and as a ratio for categorical data. Univar-
ate comparisons of these variables were performed between
aseline and follow-up variables and between subjects who
eveloped WRF versus those who did not. A paired and
npaired t test for continuous data and chi-square, Pearson’s
orrelation, and Fisher exact tests for categorical data were
sed for appropriate comparisons. The predictive value of
VP and CI as continuous variables to predict WRF was
ssessed by the use of a receiver-operating characteristic
urve analysis. Separate c-statistics for CVP and CI from
ogistic regression models were calculated, and a set of 300
ootstrapped (with replacement) samples were generated to
ompute the difference and standard error. The difference
etween the c-statistics was bias corrected, and a 1-sample
test was performed to determine whether the difference
as equal to zero. Stepwise multivariate linear regression
nalysis was used to determine the independent relation-
hips between hemodynamic variables, baseline renal func-
ion, and hemoglobin with WRF. Statistical significance
as set at a 2-tailed probability level 0.05. Statistical
nalyses were performed with SPSS for Windows, release
3.0 (SPSS Inc., Chicago, Illinois) and SAS version 8.2
Cary, North Carolina).
esults
ubject characteristics. A total of 145 subjects, mean left
entricular ejection fraction 20  8%, were included in this
bservational prospective study. Patient characteristics on
dmission are listed in Table 1 and were comparable
etween subjects who developed WRF versus those who did
ot (except for serum creatinine, blood urea nitrogen, and
emoglobin at admission). The percentage of patients with
oderate-to-severe right ventricular dysfunction (60%) was
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February 17, 2009:589–96 Venous Congestion and Worsening Renal Functionimilar between the 2 groups. Plasma B-type natriuretic
eptide measurements on admission were available in 40%
f subjects and were comparable between patients with and
ithout incident WRF (median [interquartile range]: 1,100
497, 1,921] pg/ml vs. 874 [333, 1,430] pg/ml, p  NS).
The mean time to develop WRF was 1.0  1.5 days.
ean duration of PAC-guided therapy was 3.5  1.5 days,
nd mean total length of stay was 9 9 days and was similar
etween those with or without incident WRF. On admis-
ion, 19% of the study population had severe renal insuffi-
iency, 45% had moderate renal insufficiency, and 36% had
ormal or mild renal insufficiency. Overall, 53% of patients
ho developed WRF during admission demonstrated a
erum creatinine level at discharge less than the peak serum
Baseline Patient Characteristics and Medication
Table 1 Baseline Patient Characteristics an
Patien
(n
Age (yrs) 5
NYHA functional class III to IV (%)
Ischemic etiology (%)
Body mass index (kg/m2) 2
Male sex (%)
Caucasian race (%)
Medical history (%)
Smoking history
Diabetes
Hypertension
Hyperlipidemia
ICD/CRT-D
Laboratory tests on admission
Hemoglobin (g/dl) 11
Creatinine (mg/dl) 1
GFR (ml/min/1.73 m2) 4
BUN (mg/dl) 5
Sodium (mmol/l) 13
BNP (pg/ml) 1,55
Oral medication on admission (%)
Aspirin/warfarin
ACE inhibitor/ARB
Digoxin
Beta-blockers
Spironolactone
Loop diuretics
Hydralazine
Isosorbide dinitrate
Statin
Amiodarone
Medication during PAC-guided therapy (%)
IV or oral furosemide
IV vasodilators
Milrinone
Dobutamine
Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor
cardiac resynchronization therapy with defibrillator; GFR  estimated
intravenous; NYHA  New York Heart Association; PAC  pulmonary artreatinine level. (A statistically significant correlation was observed be-
ween baseline CI and baseline renal function expressed by
erum creatinine (r  0.32, p  0.001) or GFR (r  –0.3,
 0.002). However, there was no correlation between
aseline CI and baseline CVP. Finally, no correlation
etween baseline CVP and baseline renal function could be
ound.
ncidence and renal predictors of WRF. Overall, 58
ubjects (40%) developed WRF during their hospitalization,
redominantly within the first 5 days of hospitalization. The
evelopment of WRF was associated with a greater peak of
erum creatinine (2.5  1.1 mg/dl vs. 1.5  0.8 mg/dl, p 
.001) during hospitalization. Subjects who developed WRF
ere more likely to have severe renal insufficiency at baseline
dication Use
h WRF
)
Patients Without WRF
(n  87) p Value
56 14 NS
10/90 NS
50 NS
29 4 NS
73 NS
76 NS
51 NS
34 NS
40 NS
59 NS
42/27 NS
5 13.0 1.5 0.05
9 1.5 0.8 0.007
56 25 0.05
36 20 0.001
134 5 NS
340 1,157 1,073 NS
48 NS
50 NS
43 NS
62 NS
47 0.03
86 NS
17 NS
22 NS
54 NS
19 NS
86 NS
56 NS
30 NS
27 NS
; BNP  brain natriuretic peptide; BUN  blood urea nitrogen; CRT-D 
ular filtration rate; ICD  implantable cardioverter-defibrillator; IV 
eter; WRF  worsening renal function.Use
d Me
ts Wit
 58
9 14
9/91
54
8 3
74
78
49
44
48
60
38/29
.5 2.
.9 0.
8 19
8 25
4 6
9 1,
44
49
38
56
27
80
23
27
57
22
85
51
34
30
blocker
glomerp  0.05) and had greater serum creatinine both at baseline
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Venous Congestion and Worsening Renal Function February 17, 2009:589–961.9  0.9 mg/dl vs. 1.5  0.8 mg/dl, p  0.007) and at
ischarge (2.2 1.1 mg/dl vs. 1.4 0.7 mg/dl, p 0.001).
mpact of medication on development of WRF. Subjects
ho developed WRF versus those who did not had compara-
le baseline medication use on admission, with the exception
f lower spironolactone utilization (Table 1). Overall, no
tatistically significant differences in medication use during
AC-guided therapy were observed. The mean dose of furo-
emide during intensive medical therapy guided by PAC was
imilar among patients who did and did not develop WRF
117  130 mg/day and 116  81 mg/day, respectively, p 
S). One-half of the patients in both groups received furo-
emide through continuous parental infusion.
Figure 1 Prevalence of Worsening Renal Function During Hospi
According to Categories of Admission CVP, CI, SBP, a
CI  cardiac index; Cr  serum creatinine; CVP  central venous pressure; PCWP
emodynamic Variables on Admission and Time of PAC in All Patientsccordi g to Those Who Developed WRF (n  58) a d Those W
Table 2 Hemodynamic Variables on Admission and Time of PAC iAccording to Those Who Developed WRF (n  58) a
All Patients (n  145)
Baseline Follow-Up p Value Baselin
HR (beats/min) 88 40 89 18 NS 86 2
SBP (mm Hg) 109 18 109 18 NS 111 2
CVP (mm Hg) 14 7 9 6 0.001 18 7
SPA (mm Hg) 55 15 46 7 0.001 57 1
PCWP (mm Hg) 24 7 18 5 0.001 25 7
CI (l/min/m2) 1.9 0.6 2.5 0.6 0.001 2.0 0
p  NS, †p  0.001, ‡p  0.04, §p  0.008, p  0.01 between patients who did and did not
CI cardiac index; CVP central venous pressure; HR heart rate; PCWP pulmonary capillar
bbreviations as in Table 1.aseline hemodynamic predictors of incident WRF. Table 2
llustrates the baseline hemodynamic measurements strati-
ed by the presence or absence of incident WRF. All
ubjects showed signs of impaired hemodynamics with
mpaired CI and increased right- and left-sided filling
ressures at baseline. Heart rate, systolic arterial blood
ressure, PCWP, and systolic pulmonary artery pressure at
aseline were comparable (p  NS) between the 2 cohorts
nd were not predictive for WRF.
There was an incremental risk in WRF with increasing
ategories of baseline CVP, with 75% of subjects presenting
ith a baseline CVP 24 mm Hg developing WRF (Fig. 1).
urthermore, the mean baseline CVP was statistically greater
tion
CWP
lmonary capillary wedge pressure; SBP  systolic blood pressure.
Stratifiedd Not (n  87)
Patients and Stratified
hose Who Did Not (n  87)
ts With WRF (n  58) Patients Without WRF (n  87)
Follow-Up p Value Baseline Follow-Up p Value
90 16* NS 89 46 88 19 NS
110 25* NS 108 15 109 15 NS
11 8‡ 0.001 12 6 8 5 0.001
49 15* 0.001 54 16 46 12 0.001
19 5* 0.001 24 7 18 5 0.001
2.7 0.7 0.001 1.8 0.4 2.4 0.5 0.001
worsening renal function at the same moment in time.
pressure; SBP systolic arterial blood pressure; SPA systolic pulmonary artery pressure; othertaliza
nd P
 puandho Di
n All
nd T
Patien
e
2*
1*
†
3*
*
.8§
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February 17, 2009:589–96 Venous Congestion and Worsening Renal Functionn subjects who developed WRF versus those with did not
18 7 mm Hg vs. 12 6 mm Hg, p 0.001). In addition,
significant correlation between admission CVP and severity
f WRF was found (r  0.4, p  0.0001). Estimated renal
erfusion pressure on admission was similar among patients
ho did and did not develop WRF (63  15 mm Hg vs.
5  12 mm Hg, p  0.2).
The mean baseline CI was significantly greater (rather than
ower) in subjects who developed WRF versus those who did
ot (2.0  0.8 l/min/m2 vs. 1.8  0.4 l/min/m2, p  0.008).
owever, the pattern of change in GFR during hospitalization
as similar between those with CI above and below the mean
dmission CI, indicating that changes in GFR were not related
o baseline CI. In addition, using ROC curve analysis, we
bserved that baseline CVP (0.734, p  0.0001) but not
aseline CI (0.552, p  0.6) predicted the development of
RF (difference p  0.012) (Fig. 2). In a separate ROC
nalysis (not shown), baseline CVP remained a predictor of
RF when patients were categorized according to the pres-
nce or absence of diabetes mellitus, hypertension, or signifi-
ant baseline renal dysfunction. Finally, another subanalysis
as performed in patients without severe renal insufficiency
GFR 30 ml/min/1.73 m2). In this subset, patients who
eveloped WRF still had greater admission CVP (17 4 mm
g vs. 12  5 mm Hg, p  0.007) but similar admission CI
1.9  0.4 l/min/m2 vs. 1.8 0.5 l/min/m2, p  NS).
mpact of hemodynamic changes on incident WRF. Table 2
lso compares the hemodynamic measurements from base-
ine to follow-up, stratified by the presence or absence of
Figure 2 ROC Curves for CVP and CI on
Admission for the Development of WRF
ROC  receiver-operating characteristic; WRF 
worsening renal function; other abbreviations as in Figure 1.ncident WRF. All hemodynamic alterations demonstratedignificant improvements after intensive medical therapy as
xpected (all p  0.001). Heart rate, systolic arterial blood
ressure, PCWP, and systolic pulmonary artery pressure at
he time of PAC removal remained comparable (p  NS)
etween the 2 cohorts.
ollow-up hemodynamic predictors of incident worsening
enal function. At follow-up, the mean CI remained signif-
cantly greater (2.7  0.7 l/min/m2 vs. 2.4  0.5 l/min/m2,
 0.01) and the CVP significantly greater (11  8 mm
g vs. 8  5 mm Hg, p  0.04) in subjects who developed
RF versus those who did not. In particular, a persistently
ncreased CVP8 mm Hg at the time of PAC removal was
ssociated with a greater incidence of WRF (51% vs. 18%,
 0.01). Overall discharge CVP also correlated with the
everity of WRF (r  0.3, p  0.007). Finally, discharge
VP rather than discharge CI was associated with renal
mpairment (lower GFR), as illustrated in Figure 3.
The ability of CVP on admission (p 0.01) or at time of
AC removal (p  0.03) to stratify risk to develop WRF
as apparent across the spectrum of heart rate, PCWP,
ystolic blood pressure, systolic pulmonary artery pressure,
I, serum creatinine, and hemoglobin in multivariable
nalysis.
iscussion
here have been numerous contemporary reports describing
he natural history of the development of WRF in the
etting of decompensated heart failure. However, the ma-
ority lacked careful cardiac and hemodynamic profiling
uring the clinical course of WRF. On the basis of early
ork, WRF often is attributed to hypoperfusion of the
idney due to progressive impairment of cardiac output or
ntravascular volume depletion secondary to overzealous use
f diuretics (6). We observed in our patient population with
ow-output decompensated HF that besides the presence of
ntrinsic renal insufficiency, venous congestion (both with
Figure 3 Relative Contributions of CVP
and CI to GFR at Time of PAC Removal
Error bars represent 95% confidence intervals. Cutoff values for CI  2.4
l/min/m2 and CVP  8 mm Hg. GFR  glomerular filtration rate; PAC  pulmo-
nary artery catheter; other abbreviations as in Figure 1.
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Venous Congestion and Worsening Renal Function February 17, 2009:589–96ncreased CVP on admission as well as insufficient reduction
f CVP during hospitalization) was the strongest hemody-
amic determinant for the development of WRF. In con-
rast, impaired CI on admission and improvement in CI
fter intensive medical therapy had a limited contribution to
RF. These observations provide important clinical con-
rmation of experimental data that preservation of cardiac
utput without relieving venous congestion may not neces-
arily avert the development of WRF. Although many of
hese findings may seem intuitive to the experienced clini-
ian, the concept of “congestive kidney failure” is of high
linical value with the contemporary epidemic proportions
f ADHF where cardiac insufficiency (rather than venous
ongestion) is often considered the core lesion.
The pathophysiology of WRF in the setting of ADHF is
omplex and multifactorial. The term “cardiorenal syn-
rome” is often used to describe progressive renal deterio-
ation with heart failure therapy in an aggressive attempt to
elieve congestive signs and symptoms. We chose to use the
erm “worsening renal function” because there remains
uch uncertainty regarding the precise definition of the
ardiorenal syndrome. Using a clinical surrogate of increase
n serum creatinine levels, the authors of previous reports
ave suggested that WRF occurs in one-third of patients
dmitted with ADHF (4,5,12). We found this incidence to
e even greater (approaching 40%) in a “cold and wet”
atient population. Although the initiation or maintenance
f certain classes of drugs like angiotensin-converting en-
yme inhibitors and loop diuretics has been linked to WRF,
e did not find any difference in their usage at admission or
uring hospitalization to account for the occurrence of
RF (2,13,14). The lower rates of spironolactone use in
hose developing WRF are likely due to the relative contra-
ndication of the drug in patients with intrinsic renal
iseases.
In patients with severe renal insufficiency at baseline,
lmost 60% developed WRF. Indeed, the greatest quartile
f baseline CVP and CI both had the greatest mean serum
reatinine and corresponding highest rates of WRF. This
nding indicates that the underlying intrinsic kidney disease
emains an important determinant of the “reserve” available
or the kidneys to relieve congestion and to respond to the
nsult posed by ADHF and the aggressive diuresis and
atriuresis necessary during treatment of ADHF. Naturally,
his finding also raises the question as to whether treatment
rimarily directed with the aim of “renal preservation”
hould be administered prophylactically, especially in this
xtraordinary high-risk group.
Worsening renal function occurs during the initial days
fter treatment for ADHF during hospitalization. As a
esult, the most commonly assumed cause of WRF has been
ypoperfusion of the kidney secondary to low-output or
ypotension (leading to pre-renal hypoperfusion or im-
aired renal “pre-load”) (6). In our patient population, we
bserved that systemic blood pressures were similar between
hose with versus without WRF, consistent with previous weports (2). Also, during intensive medical therapy, systolic
lood pressures were carefully monitored and targeted as
rugs were being titrated to prevent overzealous hypoten-
ion. Although we did not directly assess regional renal
erfusion, the persistently increased intracardiac pressures in
ur patient population (with a mean PCWP in the range of
8 to 19 mm Hg) suggested that the overall vasculature was
nlikely to be “under-filled.” In particular, estimated renal
erfusion pressures were similar between those with versus
ithout WRF. Clearly, judicious lowering of filling pres-
ures is still of utmost importance to prevent hypoperfusion
nd pre-renal azotemia, and there are still indicators that
areful monitoring can be helpful in vulnerable patients. For
xample, the ESCAPE (Evaluation Study of Congestive
eart Failure and Pulmonary Artery Catheterization Effec-
iveness) trial demonstrated that renal function did not
orsen when treatment was directed at lowering invasively
easured CVP and PCWP, whereas it did worsen in the
reatment arm guided by clinical assessment alone (15).
Our data also demonstrate that progressive or persistent
mpairment of cardiac output may not be the primary culprit
n the development of WRF during the treatment for
DHF. Patients who developed WRF did not have a lower
I on admission and at discharge when compared with
hose without WRF. Furthermore, the patterns of change in
FR were similar between those with a different degree of
I impairment, independent of inotropic usage. However,
his is not to imply that impairment of CI itself does not
ontribute to WRF, as we acknowledge that patients with
rogressive pump failure or cardiogenic shock may progress
o renal impairment as a result of impaired organ perfusion
r indirectly through “backward failure” and venous conges-
ion. Instead, our data indicate that in the setting of hemody-
amic alterations of ADHF on admission and after treatment,
he relative contributions of CI may be less apparent than
istorically assumed. Thus, even in this advanced heart failure
opulation with relatively low-output cardiac failure and mar-
inal blood pressures, the routine use of inotropic therapy may
ot necessarily relieve or prevent WRF.
Our observation suggests that the strongest hemody-
amic determinant of development of WRF is the presence
f venous congestion as measured by elevated CVP, both on
dmission and at follow-up. There appears to be a near-
inear relationship, because if the baseline CVP reached
16 or 24 mm Hg, we observed a sharp increase in the
ncidence of WRF approaching 59% and 75%, respectively.
uring treatment for ADHF, persistent venous congestion
lso posed a very high risk for the development of WRF.
learly, this could simply be interpreted as a “sicker” patient
opulation with more advanced disease states that were
eflected by higher CVP. However, common cardiovascular
easures of disease severity (including systolic blood pres-
ure, serum sodium, plasma B-type natriuretic peptide,
CWP, systolic pulmonary arterial pressure, and dosage of
oop diuretics) were similar between those with versus
ithout WRF.
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February 17, 2009:589–96 Venous Congestion and Worsening Renal FunctionThe concept of venous congestion being transmitted to
he renal veins and kidneys leading to renal dysfunction is
upported by a substantial amount of literature from as early
s the 1930s. In an experimental model that iatrogenically
nduced hypervolemia, an increase in renal vein pressure led
irectly to renal insufficiency independent of cardiac output
r renal blood flow (7,8). Importantly, this was also shown
o be a reversible phenomenon because lowering of renal
ein pressure immediately improved urine output and GFR
7,8). Other studies indicated that temporary renal vein
ompression resulted in reduced sodium excretion, reduced
FR, and reduced renal blood flow (16–18). Increased
VP also causes an increase in renal interstitial pressure,
hich might lead to a hypoxic state of the renal parenchyma
imilar to the mechanism by which hepatic congestion leads
o liver dysfunction in heart failure (19–25). In addition, our
roup recently provided some mechanistic data to suggest
he contributions of increased intra-abdominal pressure
aused by visceral edema or ascites in this pathophysiology
26). However, prolonged increases in plasma volume or
VP will attenuate several vascular reflexes, leading to an
mpaired arterial responsiveness, thereby further impairing
he effective renal blood flow (27–32). Increased CVP also
as been associated with reduced GFR in patients with
rimary pulmonary hypertension and relatively preserved
ardiac outputs (33). Finally, a recent subanalysis of the
SCAPE trial also suggested that incident WRF was
elated to CVP (34).
It is conceivable that, in the setting of ADHF, the
evelopment of “congestive kidney failure” led by increased
enal venous pressure from venous congestion (increased
enal afterload) and increased renal interstitial pressure
intrinsic renal compromise) might be underappreciated
echanisms by which WRF develops. These findings may
herefore help to explain why extrarenal strategies that
rimarily aim to relieve venous congestion (such as ultrafil-
ration) may be effective in alleviating “congestive kidney
ailure” in selected cases of HF rather than those augment-
ng cardiac output or forward perfusion. We believe that this
s an important conceptual shift with broad implications,
mplying that the search for future ADHF therapies should
ocus on strategies that allow safe and optimal reduction of
enous congestion to prevent such a devastating complica-
ion.
tudy limitations. There are several limitations in our
tudy, including the lack of serial weight assessments and
irect measurements on glomerular filtration. There were
o direct physiological measurements of renal hemodynam-
cs or regional intravascular volume to fully explain the
omplex underlying pathophysiology, although CI has been
onsidered a reasonable surrogate for renal blood flow under
he circumstances. To analyze CI, a standard resting met-
bolic rate was assumed, but overall CI assessed by Fick was
omparable to those assessed by thermodilution. Although
ifferences in hemoglobin concentration also might have
ontributed to differences in absolute oxygen delivery to theidney, arteriovenous oxygen differences on admission could
e retrieved in 50% of patients and were found to be similar
etween patients with and without WRF. The relatively low
dmission rates of neurohormonal antagonists and the
ifference in spironolactone use were probably secondary to
he underlying kidney disease, severity of the heart failure,
nd the withholding of medications due to intolerance
elated to their “cold and wet” conditions. Finally, although
nvasive measurements were used in our protocol, it is not
he intention of these data to imply the need for invasive
onitoring, but solely to understand the hemodynamic
ontributors of WRF in ADHF.
onclusions
n our cohort of patients with advanced HF admitted for
ecompensation, WRF was commonly observed despite
emodynamic improvements with intensive medical ther-
py. Our data imply that, apart from intrinsic renal insuf-
ciency, the presence of venous congestion, rather than
educed cardiac output, may be the primary hemodynamic
actor driving WRF in this patient population.
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